Immunitas Therapeutics Inc. has revealed preclinical data supporting development of its potentially first-in-class, fully human anti-CD161 antibody, IMT-380. CD161-expressing T-cell subsets have been implicated in autoimmune diseases due to their production of inflammatory cytokines and presence in inflamed tissues.